Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 9/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31416308 | 0.77 | RHEB (0.50) | RHEBDRD4DRD3DRD2AHR | |
| SCHEMBL830446 | 0.77 | RHEB (0.50) | RHEBDRD4DRD3DRD2AHR | |
| SCHEMBL1876842 | 0.77 | TYR (0.40) | RHEBAHRTYRUSP2GAA | |
| SCHEMBL3248883 | 0.74 | TYR (0.38) | RHEBAHRTYRUSP2GAA | |
| SCHEMBL7448671 | 0.74 | RHEB (0.47) | RHEBDRD4DRD3DRD2AHR | |
| SCHEMBL30774212 | 0.74 | RHEB (0.47) | RHEBDRD4DRD3DRD2AHR | |
| SCHEMBL8252615 | 0.74 | TYR (0.38) | RHEBAHRTYRUSP2GAA | |
| SCHEMBL2503153 | 0.74 | RHEB (0.40) | RHEBAHRF7LTA4HF3 | |
| SCHEMBL29415607 | 0.74 | TYR (0.38) | RHEBAHRTYRUSP2GAA | |
| SCHEMBL1075774 | 0.74 | RHEB (0.47) | RHEBDRD4DRD3DRD2AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057861-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-02-20 | — | — | US | disclosed |
| US-12138276-B2 | Halogenated psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2024-11-12 | — | — | US | disclosed |
| US-20240299427-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
| US-11998557-B2 | Halogenated psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2024-06-04 | — | — | US | disclosed |
| US-20230293558-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2023-09-21 | — | — | US | disclosed |
| EP-4208445-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-07-12 | — | — | EP | disclosed |
| CN-116348106-A | Halogenated nupharicin derivatives and methods of use | 恩维瑞克生物科学加拿大公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022047579-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12138276-B2 | Halogenated psilocybin derivatives and methods of using | CES2, MAOB, CNR1 | RHEB 2164/4885DPP4 4014/4885DRD4 137/4885 |
| US-20240299427-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | CES2, MAOB, CNR1 | RHEB 2164/4885DPP4 4014/4885DRD4 137/4885 |
| US-20230293558-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | CES2, MAOB, CNR1 | RHEB 2164/4885DPP4 4014/4885DRD4 137/4885 |
| US-11998557-B2 | Halogenated psilocybin derivatives and methods of using | CES2, MAOB, CNR1 | RHEB 2164/4885DPP4 4014/4885DRD4 137/4885 |
| US-20250057861-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | CES2, MAOB, CNR1 | RHEB 2164/4885DPP4 4014/4885DRD4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.